Morgan Stanley analyst Thibault Boutherin lowered the firm’s price target on Novo Nordisk (NVO) to DKK 550 from DKK 600 and keeps an Equal Weight rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- JPMorgan sees ‘most favored nation’ drug order facing ‘significant push back’
- Pharma Stocks Rally despite Trump’s Plan to Cut Drug Prices
- White House publishes Trump executive order aimed at lowering drug prices
- Many patients soon to be forced to switch obesity drug, NYT says
- Eli Lilly’s Zepbound Defeats Novo Nordisk’s Wegovy Once Again
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue